{"nctId":"NCT01150097","briefTitle":"Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients","startDateStruct":{"date":"2010-03-31","type":"ACTUAL"},"conditions":["Liver Transplant Recipient"],"count":284,"armGroups":[{"label":"Everolimus + reduced tacrolimus","type":"EXPERIMENTAL","interventionNames":["Drug: Tacrolimus (reduced tacrolimus)","Drug: Everolimus (reduced tacrolimus)","Drug: Corticosteroids"]},{"label":"Tacrolimus elimination","type":"EXPERIMENTAL","interventionNames":["Drug: Tacrolimus (tacrolimus elimination)","Drug: Everolimus (tacrolimus elimination)","Drug: Corticosteroids"]},{"label":"Tacrolimus control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tacrolimus (tacrolimus control)","Drug: Corticosteroids"]}],"interventions":[{"name":"Tacrolimus (reduced tacrolimus)","otherNames":["FK-506,","fujimycin,","Prograf,","Advagraf,","Protopic"]},{"name":"Everolimus (reduced tacrolimus)","otherNames":["RAD001,","Zortress,","Certican,","Afinitor"]},{"name":"Tacrolimus (tacrolimus elimination)","otherNames":["FK-506,","fujimycin,","Prograf,","Advagraf,","Protopic"]},{"name":"Everolimus (tacrolimus elimination)","otherNames":["RAD001,","Zortress,","Certican,","Afinitor"]},{"name":"Tacrolimus (tacrolimus control)","otherNames":["FK-506,","fujimycin,","Prograf,","Advagraf,","Protopic"]},{"name":"Corticosteroids","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent\n* Ability and willingness to adhere to study regimen\n* Completed core study with assigned regimen;\n\nExclusion Criteria:\n\nPatients fulfilling any of the following criteria are not eligible for inclusion in this study:\n\n* Severe hypercholesterolemia or hypertriglyceridemia.\n* Low platelet count.\n* Low white blood cell count.\n* Positive test for human immunodeficiency virus (HIV).\n* Systemic infection requiring active use of IV antibiotics.\n* Patients in a critical care setting.\n* Use of prohibited medication.\n* Use of immunosuppressive agents not utilized in the protocol.\n* Hypersensitivity to any of the study drugs or similar drugs.\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential not using a highly effective method of birth control.\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death","description":"The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death","description":"The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death","description":"The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death","description":"The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence Rate of tBPAR","description":"The number of participants who had a tBPAR was analyzed. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Renal Function","description":"Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m\\^2) = 186.3\\*(C\\^-1.154)\\*(A\\^-0.203)\\*G\\*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"16.13"},{"groupId":"OG001","value":"2.5","spread":"12.40"},{"groupId":"OG002","value":"-3.3","spread":"11.84"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":32,"n":106},"commonTop":["Diarrhoea","Hypertension","Nasopharyngitis","Hypercholesterolaemia","Fatigue"]}}}